Pharming Group NV
AEX:PHARM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pharming Group NV
Total Receivables
Pharming Group NV
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharming Group NV
AEX:PHARM
|
Total Receivables
$54.7m
|
CAGR 3-Years
26%
|
CAGR 5-Years
9%
|
CAGR 10-Years
33%
|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Total Receivables
€5.1m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Uniqure NV
NASDAQ:QURE
|
Total Receivables
$5.9m
|
CAGR 3-Years
-61%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
4%
|
|
|
argenx SE
XBRU:ARGX
|
Total Receivables
$1.2B
|
CAGR 3-Years
63%
|
CAGR 5-Years
176%
|
CAGR 10-Years
95%
|
|
|
Merus NV
NASDAQ:MRUS
|
Total Receivables
$23m
|
CAGR 3-Years
95%
|
CAGR 5-Years
58%
|
CAGR 10-Years
50%
|
|
|
LAVA Therapeutics NV
NASDAQ:LVTX
|
Total Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pharming Group NV
Glance View
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
See Also
What is Pharming Group NV's Total Receivables?
Total Receivables
54.7m
USD
Based on the financial report for Dec 31, 2025, Pharming Group NV's Total Receivables amounts to 54.7m USD.
What is Pharming Group NV's Total Receivables growth rate?
Total Receivables CAGR 10Y
33%
Over the last year, the Total Receivables growth was -1%. The average annual Total Receivables growth rates for Pharming Group NV have been 26% over the past three years , 9% over the past five years , and 33% over the past ten years .
